Vaccines containing ribavirin and methods of use thereof
The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described.
1. A method of producing a detectable amount of antibody specific for a hepatitis viral antigen in a subject from an amount of hepatitis viral antigen that does not produce detectable antibodies, consisting essentially of:
mixing said hepatitis viral antigen with an effective amount of ribavirin to produce an immunogenic composition; and
providing, in a single administration, said immunogenic composition to said subject.
2. The method of claim 1 , wherein said viral antigen is a hepatitis B viral antigen.
3. The method of claim 2 , wherein said hepatitis B viral antigen is a hepatitis B surface antigen.
4. The method of claim 1 , further comprising measuring the titer of antibodies specific for said hepatitis viral antigen.
5. The method of claim 1 , further comprising identifying a subject in need of antibodies specific for a hepatitis viral antigen.
6. The method of claim 2 , further comprising identifying a subject in need of antibodies specific for a hepatitis viral antigen.
7. The method of claim 1 , wherein said immunogenic composition is provided to said subject intranasally.
8. The method of claim 1 , wherein said immunogenic composition is provided to said subject transdermally.
9. The method of claim 1 , wherein said immunogenic composition comprises an oil.
10. The method of claim 1 , wherein said immunogenic composition is formulated for use with an injection device.
11. The method of claim 10 , wherein said injection device is an electrical injection device.
12. The method of claim 10 , wherein said injection device is a needleless injection device.